KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.80

Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies.

Antonio M Risitano, Carlos de Castro, Bing Han, Austin Kulasekararaj, Jaroslaw P Maciejewski, Phillip Scheinberg, Yasutaka Ueda, Susan Vallow, Georgina Bermann, Marion Dahlke, Rakesh Kumar, Régis Peffault de Latour

Blood Adv 9(8) 1816-1826

PMID39774762
PMCIDPMC12008622
DOI10.1182/bloodadvances.2024014652
发表日期2025-01-08
入排依据:The report describes results from Phase III randomized trials of iptacopan in paroxysmal nocturnal hemoglobinuria (PNH), which is classified as a hematologic malignancy. However, the primary/key secondary endpoints evaluated are patient-reported outcomes (fatigue and quality of life via FACIT-Fatigue and EORTC QLQ-C30) and their correlation with hematologic markers (LDH, Hb). It does not report on a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, nor does it include Kaplan-Meier estimates or hazard ratios for such an endpoint. Therefore, it fails the time_to_event criterion and is excluded from the cohort.
摘要

摘要

Iptacopan, a first-in-class, oral, selective complement factor B inhibitor, demonstrated efficacy and safety as monotherapy in C5 inhibitor (C5i)-experienced (APPLY-PNH; NCT04558918) and C5i-naive (APPOINT-PNH; NCT04820530) patients with paroxysmal nocturnal hemoglobinuria (PNH). In the APPLY-PNH and APPOINT-PNH trials, changes in fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-Fatigue]) and health-related quality of life (HRQOL; European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]) from baseline to day 168 were evaluated. The proportion of patients achieving meaningful within-patient change (MWPC) on the FACIT-Fatigue and 4 EORTC QLQ-C30 subscales was evaluated using anchor-based thresholds, and correlations between FACIT-Fatigue scores, lactate dehydrogenase (LDH), and hemoglobin (Hb) levels were assessed. In APPLY-PNH (iptacopan, n = 62; C5i, n = 33), more patients in the iptacopan versus the C5i group reached the MWPC threshold for FACIT-Fatigue (51% vs 11%). More patients achieved MWPC on EORTC QLQ-C30 subscales in the iptacopan group (39%-49%) versus the C5i group (9%-20%). In APPOINT-PNH (N = 40), 56% achieved MWPC on the FACIT-Fatigue, and the proportion of patients who achieved MWPC on the EORTC QLQ-C30 ranged from 41% to 55%. In C5i-experienced patients, increased Hb levels correlated with improvement in FACIT-Fatigue scores (R = 0.48); in C5i-naive patients, increased Hb (R = 0.42) and decreased LDH (R = -0.53) (all P < .001) correlated with improved FACIT-Fatigue scores. C5i-experienced and -naive patients receiving iptacopan exhibited meaningful improvement in fatigue, HRQOL, and disease-related symptoms, which correlated with clinical improvement in hematologic markers of disease control.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。